This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-30. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
A band cell (also called band neutrophil, band form or stab cell) is a cell undergoing granulopoiesis, derived from a metamyelocyte, and leading to a mature granulocyte. It is characterized by having a curved but not lobular nucleus. The term "band cell" implies a granulocytic lineage (e.g., neutrophils).
Using these techniques, a model of human metabolism has now been produced, which will guide future drug discovery and biochemical research. These models are now used in network analysis, to classify human diseases into groups that share common proteins or metabolites. Bacterial metabolic networks are a striking example of bow-tie organization, an architecture able to input a wide range of nutrients and produce a large variety of products and complex macromolecules using a relatively few intermediate common currencies. A major technological application of this information is metabolic engineering. Here, organisms such as yeast, plants or bacteria are genetically modified to make them more useful in red biotechnology and aid the production of drugs such as antibiotics or industrial chemicals such as 1,3-propanediol and shikimic acid. These genetic modifications usually aim to reduce the amount of energy used to produce the product, increase yields and reduce the production of wastes.
==== Buspirone ==== Buspirone (Buspar) is a 5-HT1A receptor agonist used to treat generalized anxiety disorder. If an individual has only recently stopped taking benzodiazepines, buspirone will be less effective.
AGE HMGB1 (Amphoterin) S100A12 (EN-RAGE) S100B S100A7 (psoriasin) but not highly homologous S100A7A (koebnerisin) S100P S100A8/A9 complex referred to as calprotectin Amyloid-β-protein Mac-1 Phosphatidylserine. S100A4
Sources: en.wikipedia.org
== Synthesis == The synthesis (in this case, of carbon-14-labelled material) can be seen in figure 1. In the first step, o-nitroaniline (compound 1) is purified through dissolution in hot water-ethanol mixture in relation 2:1. [Activated carbon] is added and the result is filtrated for clarifying. The filtrate is chilled while kept in movement to generate crystals, usually at 4 °C, but if needed it can also be cooled to −10 °C. The crystals are then collected, washed and dried. If it is pure enough it is used for the following steps, which take place at 0 till 5 °C. To produce o-Nitrobenzonitrile-14C (compound 2), the first component o-nitroaniline and (concentrated reagent grade) hydrochloric acid are put together with ice and water. Sodium nitrite, dissolved in water, is added to this thin slurry. After the formation of a pale-yellow solution, which indicates the completion of the diazotization reaction, the pH should be adjusted to 6. After this, the solution is introduced to a mixture of cuprous cyanide and toluene. At room temperature the toluene layer is removed. The aqueous layer is washed and dried and the purified product is isolated by crystallization. The third product is Anthranilamide-14C (compound 3). It is formed out of o-Nitrobenzonitrile-14C, which is first solved in ethanol and hydrazine hydrate. The solvent is heated subsequently, treated in a well-ventilated hood with small periodic charges, smaller than 10 mg, of Raney nickel. Under nitrogen atmosphere the ethanolic solution is clarified and dried.
Upon release, the album was met with widespread acclaim from critics. According to the review aggregator Metacritic, Let God Sort Em Out received "universal acclaim" based on a weighted average score of 83 out of 100 from eleven critic scores. Alexis Petridis of The Guardian gave the album a perfect score and called it "as strong a restatement of Clipse's skills and power as you could wish for". The lyrical versatility was praised ("Great lines abound, from the chilling to the laugh-out-loud"), as were the duo's chemistry; the guest appearances, which were said to have "step[ped] up" without stealing the show; and the "inspired" production. He concluded by declaring it one of the best albums of the year. Tom Breihan of Stereogum shared similar sentiments when reviewing the album for the publication's Premature Evaluation column, commenting on its "minimal, stabbing intensity" that he likened to Clipse's second album, Hell Hath No Fury (2006). Lyrically, he also praised the duo's chemistry with the featured guests—Stove God Cooks and Ab-Liva in particular—and Malice's presence, which "still has the gravitational force of a black hole". Niall Smith of Clash gave the album a nine out of ten and described the lyrics as a balance between the duo's old style and introspection on "maturity, perspective[,] and loss". Smith felt that the album's most impressive aspect was the guest appearances; although he felt some of Williams's choruses were "shakier moments", they were mostly redeemed by Clipse's "synergy".
The absence of plutonium-238 contamination in atmospheric and seawater sampling confirmed the assumption that the cask is intact on the seabed. The cask is expected to contain the fuel for at least 10 half-lives (870 years). The US Department of Energy has conducted seawater tests and determined that the graphite casing, which was designed to withstand reentry, is stable and no release of plutonium should occur. Subsequent investigations have found no increase in the natural background radiation in the area. The Apollo 13 accident represents an extreme scenario because of the high re-entry velocities of the craft returning from cis-lunar space (the region between Earth's atmosphere and the Moon). This accident has served to validate the design of later-generation RTGs as highly safe. Mars 96 was launched by Russia in 1996, but failed to leave Earth orbit, and re-entered the atmosphere a few hours later. The two RTGs onboard carried in total 200 g of plutonium and are assumed to have survived reentry as they were designed to do. They are thought to now lie somewhere in a northeast–southwest running oval 320 km long by 80 km wide which is centred 32 km east of Iquique, Chile.
== Method == Classically, to perform a radioimmunoassay, a known quantity of an antigen is made radioactive, frequently by labeling it with gamma-radioactive isotopes of iodine, such as 125-I, or tritium attached to tyrosine. This radiolabeled antigen is then mixed with a known amount of antibody for that antigen, and as a result, the two specifically bind to one another. Then, a sample of serum from a patient containing an unknown quantity of that same antigen is added. This causes the unlabeled (or "cold") antigen from the serum to compete with the radiolabeled antigen ("hot") for antibody binding sites. As the concentration of "cold" antigen is increased, more of it binds to the antibody, displacing the radiolabeled variant, and reducing the ratio of antibody-bound radiolabeled antigen to free radiolabeled antigen. The bound antigens are then separated and the radioactivity of the free(unbound) antigen remaining in the supernatant is measured using a gamma counter. This value is then compared to a standardised calibration curve to work out the concentration of the unlabelled antigen in the patient serum sample. This method can be used for any biological molecule in principle and is not restricted to serum antigens, nor is it required to use the indirect method of measuring the free antigen instead of directly measuring the captured antigen.
== Background == Pedro Cuatrecasas was born in Madrid, Spain on 27 September 1936. He completed his A.B. from Washington University in St. Louis in 1958. He completed his M.D. from Washington University School of Medicine in 1962. Cuatrecasas died in La Jolla, California on 19 March 2025, at the age of 88.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.